Modality
ADC
MOA
CGRPant
Target
LAG-3
Pathway
Wnt
MigraineMM
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Jan 2030
Phase 2Current
NCT04495524
663 pts·Migraine
2020-09→2028-07·Completed
NCT03250318
1,276 pts·Migraine
2017-04→2030-01·Recruiting
1,939 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-269mo awayOrphan Drug· Migraine
2028-07-102.3y awayPh2 Data· Migraine
2030-01-053.8y awayPh2 Data· Migraine
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Recruit…
P2
Complet…
Catalysts
Orphan Drug
2026-12-26 · 9mo away
Migraine
Ph2 Data
2028-07-10 · 2.3y away
Migraine
Ph2 Data
2030-01-05 · 3.8y away
Migraine
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04495524 | Phase 2 | Migraine | Completed | 663 | eGFR |
| NCT03250318 | Phase 2 | Migraine | Recruiting | 1276 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |